Amikacin, Peak

Also known as: Amikin®

Clinical Use

Use

Amikacin is used to treat serious infections caused by susceptible aerobic gram-negative bacilli (eg, a number of the Enterobacteriaceae, P aeruginosa). Such infections include bacteremias; intra-abdominal, soft tissue (including burns), bone or joint, lower respiratory tract, and complicated urinary tract infections, and meningitis.

Special Instructions

Not provided.

Limitations

Amikacin therapy may result in nephrotoxicity in 10-25% of patients receiving aminoglycosides, predominantly due to prolonged high trough levels. Monitoring of plasma levels is essential to avoid this risk. Aminoglycosides may also cause ototoxicity, although it's uncommon when levels are closely monitored and dosing is adjusted. High peak serum concentrations from new dosing regimens do not necessarily enhance toxicity, complicating therapeutic monitoring.

Test Details

Methodology

Immunoassay (IA)

Biomarkers

Amikacin

Analyte

Concentration / Level

Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)

LOINC Codes

Order Codes

3319-1 - Amikacin Peak SerPl-mCnc

Result Codes

3319-1 - Amikacin Peak SerPl-mCnc

Result Turnaround Time

1-3 days

Specimen

Serum

Volume

1 mL

Minimum Volume

0.3 mL

Container

Red-top tube or green-top (heparin) tube. Do not use a gel-barrier tube.

Collection Instructions

Transfer separated serum or plasma to a plastic transport tube. Peak samples are drawn 60 minutes after an IM injection, 30 minutes after a 30-minute IV infusion, or immediately after a 60-minute IV infusion.